title: [Neoadjuvant Chemotherapy for Gastric Cancer].
abstract: Adjuvant chemotherapy aims to eradicate residual micro-metastatic tumor cells existing at distant sites outside the surgical field. The current standard adjuvant chemotherapy is S-1 for 1 year or capecitabine plus oxaliplatin for 6 months after D2 gastrectomy. However, there are some rooms in the overall survival of Stage III. Neoadjuvant chemotherapy(NAC)is a promising approach that combines intensive chemotherapy with high compliance; however, it is under development in Japan. Two JCOG phase II trials suggested that NAC was effective for bulky nodal disease. For scirrhous-type malignancy, a JCOG phase III trial is currently ongoing investigating the efficacy of a NAC regimen of S-1 plus CDDP. Another group is conducting 2 randomized phase II trials to compare different regimens and courses of NAC. So far, 2 courses of S-1 plus CDDP or 3 courses of S-1 plus oxaliplatin can be recommended as candidates for the test arm of future phase III studies of NAC.
authors.affiliation: Dept. of Gastrointestinal Surgery, Kanagawa Cancer Center.
authors.forename: Takaki
authors.initials: T
authors.lastname: Yoshikawa
authors.forename: Tsutomu
authors.initials: T
authors.lastname: Sato
authors.forename: Takanobu
authors.initials: T
authors.lastname: Yamada
authors.forename: Toru
authors.initials: T
authors.lastname: Aoyama
authors.forename: Takashi
authors.initials: T
authors.lastname: Ogata
authors.forename: Haruhiko
authors.initials: H
authors.lastname: Cho
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D017024:Chemotherapy, Adjuvant; D002986:Clinical Trials as Topic; D005743:Gastrectomy; D006801:Humans; D020360:Neoadjuvant Therapy; D009367:Neoplasm Staging; D013274:Stomach Neoplasms / Q000175:diagnosis / Q000188:drug therapy* / Q000601:surgery
chemical_list: D000970:Antineoplastic Agents